ProPath Appoints Soft Tissue Tumor Expert, Julia A. Bridge, M.D., as Director of Cytogenetics and FISH – Business Wire

DALLAS--(BUSINESS WIRE)--ProPath, the largest fully physician-owned pathology practice in the United States, today announced that Julia A. Bridge, M.D., a board-certified pathologist and geneticist with an extensive medical career and expertise in solid tumor molecular testing, has joined the ProPath team.

Dr. Bridge, who recently directed the Molecular Pathology Research Division at the Translational Genomics Research Institute in Phoenix, AZ, will be directing ProPaths fluorescence in situ hybridization (FISH) and cytogenetics team. She will also be incorporating her testing expertise in bone/soft tissue tumors for ProPaths molecular pathology team.

We are thrilled to have Dr. Bridge join our team, said Cory A. Roberts, M.D., President, Chairman and CEO of ProPath. She has a rare combination of expertise in both anatomic pathology and cytogenetics that make her an expert with an international consultative practice. Her ability to interpret microscopic morphology in concert with her unsurpassed knowledge of the molecular and genetic signature of tumors is unsurpassed and will carry ProPaths abilities in these areas to the forefront of all practices.

Dr. Bridge received her medical degree from the University of Nebraska Medical Center and completed her pathology residency at the University of Kansas Medical Center followed by clinical cytogenetic and molecular fellowships at the University of Nebraska Medical Center and the Southwest Biomedical Research Institute in Scottsdale Arizona.

Dr. Bridge serves or has served on editorial boards for pathology, orthopedic, and genetics journals, in consulting or advisory board positions for cancer networks and industry (including as key investigator for landmark FDA approvals for two novel gene-based tests), the national Childrens Oncology Group Soft Tissue Sarcoma and Ewing sarcoma committees, College of American Pathology (CAP) Glioma Expert Panel, and Secretarial Appointee to the national Department of Veterans Affairs Genomic Medicine Program Advisory Committee. She has authored greater than 300 scientific articles, chapters, review papers, digital and web-based materials, and is co-author or co-editor of several books (e.g. AFIP Atlas of Tumor Pathology; 4th Series, Fascicle 2: Tumors of the Bones and Joints and editions of the WHO Classification of Tumours of Soft Tissue and Bone). Dr. Bridge is the current President of the United States and Canadian Academy of Pathology.

About ProPath:

ProPath is the largest, nationwide, fully physician-owned pathology practice in the United States. Led by a team of world-class physicians and scientists, ProPath routinely diagnoses cases from 45 states and several foreign countries. Its over 500 employees reside in 10 states and staff labs and facilities in three states. For 55 years, ProPaths mission has been to provide patient-centered, high quality and effective medical diagnostics, prognostics and research that creates better patient outcomes.

Continue reading here:
ProPath Appoints Soft Tissue Tumor Expert, Julia A. Bridge, M.D., as Director of Cytogenetics and FISH - Business Wire